188 related articles for article (PubMed ID: 23957630)
1. Chronic myeloid leukemia: reaching for the cure.
Nencioni A; Cea M; Montecucco F; Gobbi M; Patrone F
Curr Cancer Drug Targets; 2013 Sep; 13(7):709-10. PubMed ID: 23957630
[No Abstract] [Full Text] [Related]
2. New insights into biology of chronic myeloid leukemia: implications in therapy.
Cea M; Cagnetta A; Nencioni A; Gobbi M; Patrone F
Curr Cancer Drug Targets; 2013 Sep; 13(7):711-23. PubMed ID: 23906052
[TBL] [Abstract][Full Text] [Related]
3. Management of early stage chronic myeloid leukemia: state-of-the-art approach and future perspectives.
Galaverna F; Ghiggi C; Guolo F; Beltrami G; Dellepiane C; Giannoni L; Carella A; Carella AM
Curr Cancer Drug Targets; 2013 Sep; 13(7):749-54. PubMed ID: 23952099
[TBL] [Abstract][Full Text] [Related]
4. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
5. Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence.
Inoue A; Kobayashi CI; Shinohara H; Miyamoto K; Yamauchi N; Yuda J; Akao Y; Minami Y
Int J Hematol; 2018 Oct; 108(4):365-370. PubMed ID: 30155588
[TBL] [Abstract][Full Text] [Related]
6. Evaluating treatment response of chronic myeloid leukemia: emerging science and technology.
Cagnetta A; Garuti A; Marani C; Cea M; Miglino M; Rocco I; Palermo C; Fugazza G; Cirmena G; Colombo N; Grasso R; Nencioni A; Gobbi M; Patrone F
Curr Cancer Drug Targets; 2013 Sep; 13(7):779-90. PubMed ID: 23906053
[TBL] [Abstract][Full Text] [Related]
7. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
Yang K; Fu LW
Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000
[TBL] [Abstract][Full Text] [Related]
9. Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy.
Proschmann R; Baldow C; Rothe T; Suttorp M; Thiede C; Tauer JT; Müller MC; Hochhaus A; Roeder I; Glauche I
Haematologica; 2017 Feb; 102(2):e39-e42. PubMed ID: 27856510
[No Abstract] [Full Text] [Related]
10. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
Carella AM
Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645
[No Abstract] [Full Text] [Related]
11. Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.
Eiring AM; Deininger MW
Genome Biol; 2014 Sep; 15(9):461. PubMed ID: 25316524
[TBL] [Abstract][Full Text] [Related]
12. Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy.
Helgason GV; Mukhopadhyay A; Karvela M; Salomoni P; Calabretta B; Holyoake TL
Curr Cancer Drug Targets; 2013 Sep; 13(7):724-34. PubMed ID: 23941517
[TBL] [Abstract][Full Text] [Related]
13. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Perel JM; McCarthy C; Walker O; Irving I; Williams B; Kennedy GA
Haematologica; 2005 Nov; 90 Suppl():ECR25. PubMed ID: 16266916
[No Abstract] [Full Text] [Related]
15. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
O'Hare T; Eide CA; Deininger MW
Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia.
Yeung DT; Hughes TP
Crit Rev Oncog; 2012; 17(1):17-30. PubMed ID: 22471662
[TBL] [Abstract][Full Text] [Related]
17. [Chronic myeloid leukemia as a model for the development and therapeutic use of tyrosine kinase inhibitors].
López-Karpovitch X
Rev Invest Clin; 2003; 55(2):191-5. PubMed ID: 12827926
[No Abstract] [Full Text] [Related]
18. Editorial: CML HSCs: Are the True Enemies for the Patient?
Mancini M
Curr Drug Targets; 2017; 18(4):376. PubMed ID: 28264644
[No Abstract] [Full Text] [Related]
19. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
[TBL] [Abstract][Full Text] [Related]
20. Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation.
Lu XY; Cai Q; Ding K
Curr Med Chem; 2011; 18(14):2146-57. PubMed ID: 21517764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
